The three Es of cancer immunoediting - PubMed (original) (raw)
Review
The three Es of cancer immunoediting
Gavin P Dunn et al. Annu Rev Immunol. 2004.
Free article
Abstract
After a century of controversy, the notion that the immune system regulates cancer development is experiencing a new resurgence. An overwhelming amount of data from animal models--together with compelling data from human patients--indicate that a functional cancer immunosurveillance process indeed exists that acts as an extrinsic tumor suppressor. However, it has also become clear that the immune system can facilitate tumor progression, at least in part, by sculpting the immunogenic phenotype of tumors as they develop. The recognition that immunity plays a dual role in the complex interactions between tumors and the host prompted a refinement of the cancer immunosurveillance hypothesis into one termed "cancer immunoediting." In this review, we summarize the history of the cancer immunosurveillance controversy and discuss its resolution and evolution into the three Es of cancer immunoediting--elimination, equilibrium, and escape.
Similar articles
- Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium.
Curigliano G, Criscitiello C, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A. Curigliano G, et al. Breast. 2013 Aug;22 Suppl 2:S96-9. doi: 10.1016/j.breast.2013.07.018. Breast. 2013. PMID: 24074802 Review. - Human leukocyte antigen-G and cancer immunoediting.
Urosevic M, Dummer R. Urosevic M, et al. Cancer Res. 2008 Feb 1;68(3):627-30. doi: 10.1158/0008-5472.CAN-07-2704. Cancer Res. 2008. PMID: 18245459 Review. - The immunobiology of cancer immunosurveillance and immunoediting.
Dunn GP, Old LJ, Schreiber RD. Dunn GP, et al. Immunity. 2004 Aug;21(2):137-48. doi: 10.1016/j.immuni.2004.07.017. Immunity. 2004. PMID: 15308095 Review. - Cancer immunoediting: from immunosurveillance to tumor escape.
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Dunn GP, et al. Nat Immunol. 2002 Nov;3(11):991-8. doi: 10.1038/ni1102-991. Nat Immunol. 2002. PMID: 12407406 Review. - Cancer immunosurveillance and immunoediting by natural killer cells.
Gross E, Sunwoo JB, Bui JD. Gross E, et al. Cancer J. 2013 Nov-Dec;19(6):483-9. doi: 10.1097/PPO.0000000000000005. Cancer J. 2013. PMID: 24270347 Review.
Cited by
- Combining radiotherapy and cancer immunotherapy: a paradigm shift.
Formenti SC, Demaria S. Formenti SC, et al. J Natl Cancer Inst. 2013 Feb 20;105(4):256-65. doi: 10.1093/jnci/djs629. Epub 2013 Jan 4. J Natl Cancer Inst. 2013. PMID: 23291374 Free PMC article. Review. - Regulatory considerations for clinical development of cancer vaccines.
Heelan BT. Heelan BT. Hum Vaccin Immunother. 2014;10(11):3409-14. doi: 10.4161/21645515.2014.982999. Hum Vaccin Immunother. 2014. PMID: 25625933 Free PMC article. Review. - [Current update on dermatomyositis].
Steininger J, Günther C. Steininger J, et al. Dermatologie (Heidelb). 2024 Feb;75(2):153-162. doi: 10.1007/s00105-023-05273-9. Epub 2024 Jan 9. Dermatologie (Heidelb). 2024. PMID: 38194097 German. - Advances in immunotherapy for the treatment of glioblastoma.
Tivnan A, Heilinger T, Lavelle EC, Prehn JH. Tivnan A, et al. J Neurooncol. 2017 Jan;131(1):1-9. doi: 10.1007/s11060-016-2299-2. Epub 2016 Oct 14. J Neurooncol. 2017. PMID: 27743144 Free PMC article. Review. - Eosinophils in glioblastoma biology.
Curran CS, Bertics PJ. Curran CS, et al. J Neuroinflammation. 2012 Jan 17;9:11. doi: 10.1186/1742-2094-9-11. J Neuroinflammation. 2012. PMID: 22251275 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources